CoChat

Human serum albumin nanoparticles for ocular delivery of bevacizumab

Open access
Luis de Redín, Inés, Boiero, Carolina, Martínez-Ohárriz, María Cristina, Agüeros, Maite, Ramos, Rocío, Peñuelas, Iván, Allemandi, Daniel, Llabot, Juan M., Irache, Juan M. · 2018 · International Journal of Pharmaceutics
Cited by 73

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

Bevacizumab-loaded nanoparticles (B-NP) were prepared by a desolvation process followed by freeze-drying, without any chemical, physical or enzymatic cross-linkage. Compared with typical HSA nanoparticles cross-linked with glutaraldehyde (B-NP-GLU), B-NP displayed a significantly higher mean size (310 nm vs. 180 nm) and a lower negative zeta potential (-15 mV vs. -36 mV). On the contrary, B-NP displayed a high payload of approximately 13% when measured by a specific ELISA, whereas B-NP-GLU presented a very low bevacizumab loading (0.1 μg/mg). These results could be related to the inactivation of bevacizumab after reacting with glutaraldehyde. From B-NP, bevacizumab was released following an initial burst effect, proceeded by a continuous release of bevacizumab at a rate of 6 μg/h. Cytotoxicity studies in ARPE cells were carried out at a single dose up to 72 h and with repeated doses over a 5-day period. Neither bevacizumab nor B-NP altered cell viability even when repeated doses were used. Finally, B-NP were labeled with 99mTc and administered as eye drops in rats. 99mTc-B-NP remained in the eye for at least 4 h while 99mTc-HSA was rapidly drained from the administration point. In summary, HSA nanoparticles may be an appropriate candidate for ocular delivery of bevacizumab.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ijpharm.2018.02.003

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 73

Metadata

Authors
Luis de Redín, I., Boiero, C., Martínez-Ohárriz, M. C., Agüeros, M., Ramos, R., Peñuelas, I., Allemandi, D., Llabot, J. M., & Irache, J. M.
Venue
International Journal of Pharmaceutics
Publisher
Elsevier BV
Published
2018-04
Volume
541
Issue
1-2
Pages
214-223
ISSN
0378-5173 (ISSN-L)
OpenAlex
W2791537102
Cited by
73
References
3
FWCI
3.79
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Human serum albumin nanoparticles for ocular delivery of bevacizumab. https://app.cochat.ai/papers/10.1016/j.ijpharm.2018.02.003
The paper
Luis de Redín, I., Boiero, C., Martínez-Ohárriz, M. C., Agüeros, M., Ramos, R., Peñuelas, I., Allemandi, D., Llabot, J. M., & Irache, J. M. (2018). Human serum albumin nanoparticles for ocular delivery of bevacizumab. International Journal of Pharmaceutics. https://doi.org/10.1016/j.ijpharm.2018.02.003

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.